miR-30e* is an independent subtype-specific prognostic marker in breast cancer

Abstract

Background:Breast cancer clinical outcome is affected by tumor molecular features, and the identification of subtype-specific prognostic biomarkers is relevant for breast cancer translational research. Gene expression signatures proved to be able to complement prognostic information provided by classical clinico-pathological features. Recently, microRNAs (miRNAs) have been causally linked to tumorigenesis and cancer progression and have been associated with patient outcome, also in breast cancer.Methods:MicroRNAs associated with the development of distant metastasis were identified in a cohort of 92 ESR1+/ERBB2− lymph node-negative breast cancers from patients not receiving adjuvant treatment. Results were confirmed and further investigated in a total of 1246 miRNA and gene expression profiles of the Molecular Taxonomy of Breast Cancer International Consortium data set. Moderated t-test, univariable and multivariable Cox regression models were used for statistical analyses.Results:miR-30e* was identified as independent protective prognostic factor in lymph node-negative untreated patients with ESR1+/ERBB2− tumours and retained a significant association with a good prognosis in treated patients with the same tumor subtype as well as in the ERBB2+ subtype, but not in ESR1−/ERBB2− tumours.Conclusions:We highlighted a relevant and subtype-specific role in breast cancer for miR-30e* and demonstrated that adding miRNA markers to gene signatures and clinico-pathological features can help for a better prognostication.

SOX2 regulates multiple malignant processes of breast cancer development through the SOX2/miR-181a-5p, miR-30e-5p/TUSC3 axis

“…By contrast, we have just begun to elicit the role of miR-30e-5p in tumour development. Tissue microarray analysis suggests that high levels of miR-30e-5p in primary tumours are associated with a favourable prognosis in breast cancer [60]. In our study, we observed increased levels of miR-181a-5p and miR-30e-5p in breast cancer biopsies as compared to normal mammary gland tissue.…”

Noncoding RNAs in breast cancer

“…Expression levels of a number of miRNAs, which are either positively or inversely associated with metastatic status, disease-free time and overall survival of breast cancer patients have been identified [225][226][227][228][229][230][231][232][233][234][235][236][237][238][239][240] and are detailed in Table 3. The most relevant miRNA with prognostic value in breast cancer is miR-210, the aforementioned oncogenic miRNA implicated in the DCIS-to-IDC transition.…”

“…tissue miR-30 e* miR-30 e* was identified as independent protective prognostic factor in lymph node-negative untreated patients with ESR1þ/ERBB2-tumors [240] miRNA-based oligonucleotides to increase their in vivo stability and binding affinity to endogenous RNA targets. Given that naked nucleic acid molecules are not generally suitable for in vivo applications owing to their intrinsic negative charge, packaging of the gene silencing agents (e.g.…”

miR-199a-5p confers tumor-suppressive role in triple-negative breast cancer

“…Accumulating evidence demonstrated that miRNAs show distinct expression signatures across different cancer subtypes, and have either oncogenic or tumor-suppressive roles [17, 18]. Our previous study discovered that miR-199a-5p showed low expression in TNBC patients’ circulation when compared with other subtypes of breast cancers, also the expression level was linked with disease stage, and suggested to be a potential biomarker for TNBC [19].…”